Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma

LESSONS LEARNED. Due to evolving imaging criteria in brain tumors and variation in magnetic resonance imaging evaluation, it is not ideal to use response rate as a primary objective. Future studies involving antiangiogenic agents should use overall survival. Disease‐expected toxicities should be con...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncologist
Hoofdauteurs: Affronti, Mary Lou, Jackman, Jennifer Gamboa, McSherry, Frances, Herndon, James E., Massey, Elwood C., Lipp, Eric, Desjardins, Annick, Friedman, Henry S., Vlahovic, Gordana, Vredenburgh, James, Peters, Katherine B.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: AlphaMed Press 2018
Onderwerpen:
Clinical Trial Results
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6156179/
https://ncbi.nlm.nih.gov/pubmed/29666296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0149
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items